Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Status:
Terminated
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy combined with chemotherapy as a possible
treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
The drugs involved in this study are:
- Prexasertib (LY2606368)
- Mitoxantrone
- Etoposide
- Cytarabine